← Leaderboards
Steven Monroe Lipkin
Weill Medical Coll Of Cornell Univ
$27,661,021
Attributed
$33,185,197
Total exposure
30
Grants
27
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,525,110 · 31
By mechanism
R01$15,541,509 · 7
N01$8,406,355 · 4
U54$6,057,364 · 7
U01$3,761,146 · 1
R21$1,491,260 · 4
K22$446,310 · 1
Top collaborators
- Eduardo Vilar Sanchez10 shared
- Kenneth Offit5 shared
- Haiyuan Yu4 shared
- Nasser Khaled Altorki3 shared
- Timothy E Mcgraw3 shared
- Vivek Mittal3 shared
- Richard Lipkin1 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Nasser Khaled Altorki$2,970,612
- Vivek Mittal$10,850,597
- Gregory F Sonnenberg$27,142,830
- Julie Magarian Blander$17,921,173
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorMutationInnovationGenesInsightHereditary Nonpolyposis Colorectal NeoplasmsIn VivoCellsMouse ModelMismatch RepairClinical TrialsBaseGene MutationColorectal CancerInsertion/Deletion MutationImmunogenicAdenomaImmuneAffectPeptidesNeoantigensImmunogenicityVaccines
Grant awards (94)
Cancer Immune-Interception for Lynch Syndrome$672,260
R01 · FY2025 · CA
CAP-IT Center for LNP RNA Immunoprevention$1,060,438
U54 · FY2024 · CA · contact PI
Cancer Immune-Interception for Lynch Syndrome$639,370
R01 · FY2024 · CA
Lung Cancer Vaccine$433,293
U54 · FY2024 · CA · contact PI
Lynch Vaccine$345,292
U54 · FY2024 · CA · contact PI
The Computational Tumor Immunology Core (CTIC)$166,192
U54 · FY2024 · CA · contact PI
CAP-IT CRI U54 ADMINISTRATIVE CORE$115,661
U54 · FY2024 · CA · contact PI
Contract Orientation and Kickoff Meeting$3,500
N01 · FY2024 · CA · contact PI
CAP-IT Center for LNP RNA Immunoprevention$1,098,880
U54 · FY2023 · CA · contact PI
Cancer Immune-Interception for Lynch Syndrome$660,089
R01 · FY2023 · CA
Lung Cancer Vaccine$440,288
U54 · FY2023 · CA · contact PI
Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer$379,977
R01 · FY2023 · CA · contact PI
Lynch Vaccine$360,907
U54 · FY2023 · CA · contact PI
The Computational Tumor Immunology Core (CTIC)$183,927
U54 · FY2023 · CA · contact PI
CAP-IT CRI U54 ADMINISTRATIVE CORE$113,758
U54 · FY2023 · CA · contact PI
CAP-IT Center for LNP RNA Immunoprevention$1,180,595
U54 · FY2022 · CA · contact PI
Neoantigen Vaccination for Lynch Syndrome Immunoprevention$780,309
U01 · FY2022 · CA · contact PI
Cancer Immune-Interception for Lynch Syndrome$661,865
R01 · FY2022 · CA
Lynch Vaccine$441,081
U54 · FY2022 · CA · contact PI
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance$408,435
R01 · FY2022 · CA · contact PI
Validating novel DNA repair deficient cancer therapy targets and small molecule compounds$398,917
R41 · FY2022 · CA · contact PI
Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer$379,977
R01 · FY2022 · CA · contact PI
CAP-IT CRI U54 ADMINISTRATIVE CORE$117,052
U54 · FY2022 · CA · contact PI
Cancer Immune-Interception for Lynch Syndrome$692,579
R01 · FY2021 · CA
Neoantigen Vaccination for Lynch Syndrome Immunoprevention$638,061
U01 · FY2021 · CA · contact PI
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance$503,240
R01 · FY2021 · CA · contact PI
Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer$387,731
R01 · FY2021 · CA · contact PI
Neoantigen Vaccination for Lynch Syndrome Immunoprevention$771,608
U01 · FY2020 · CA · contact PI
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance$451,010
R01 · FY2020 · CA · contact PI
Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer$387,731
R01 · FY2020 · CA · contact PI
Neoantigen Vaccination for Lynch Syndrome Immunoprevention$717,507
U01 · FY2019 · CA · contact PI
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance$485,477
R01 · FY2019 · CA · contact PI
Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer$387,731
R01 · FY2019 · CA · contact PI
ANTI FUSOBACTERIUM NUCLEATUM VACCINE FOR COLORECTAL CANCER IMMUNOPREVENTION$49,995
N01 · FY2019 · CA · contact PI
Frameshift peptide vaccine for the prevention Lynch syndrome-associated gastrointestinal cancer HHSN2612015000391 TORFP: 2018-E12 POP: 9/17/2018 to 3/16/2021$894,832
N01 · FY2018 · CA · contact PI
Neoantigen Vaccination for Lynch Syndrome Immunoprevention$853,661
U01 · FY2018 · CA · contact PI
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance$501,220
R01 · FY2018 · CA · contact PI
IGF::OT::IGF ANTI FUSOBACTERIUM NUCLEATUM VACCINE FOR COLORECTAL CANCER IMMUNOPREVENTION$476,619
N01 · FY2017 · CA · contact PI
IGF::OT::IGF TESTING OF COMBINATION IMMUNO AND CHEMOPREVENTION STRATEGIES FOR LYNCH SYNDROME GASTROINTESTINAL CANCER$151,260
N01 · FY2017 · CA · contact PI
Whole Genome Sequencing to Discover Familial Myeloma Risk Genes$494,158
R01 · FY2016 · CA · contact PI
IGF::OT::IGF ANTI FUSOBACTERIUM NUCLEATUM VACCINE FOR COLORECTAL CANCER IMMUNOPREVENTION$423,381
N01 · FY2016 · CA · contact PI
Using Protein Interactome Networks to Understand the Functional Role of Coding DN$404,060
R01 · FY2016 · GM · contact PI
IGF::OT::IGF TESTING OF COMBINATION IMMUNO AND CHEMOPREVENTION STRATEGIES FOR LYNCH SYNDROME GASTROINTESTINAL CANCER$679,964
N01 · FY2015 · CA · contact PI
Using Protein Interactome Networks to Understand the Functional Role of Coding DN$410,178
R01 · FY2015 · GM · contact PI
Mechanisms of host-bacterial interactions, ileitis and granuloma formation in Agr$361,770
R01 · FY2015 · DK · contact PI
Whole Genome Sequencing to Discover Familial Myeloma Risk Genes$350,675
R01 · FY2015 · CA · contact PI
IGF::OT::IGF CONTRACT ORIENTATION AND KICKOFF MEETING$3,205
N01 · FY2015 · CA · contact PI
IGF::OT::IGF Base Contract Title: Preclinical In Vitro and In Vivo Agent Development Assays, Task Order Title: A Polyvalent Vaccine Against Fusion Proteins Observed in Solid Tumors, Period of Perfo$458,635
N01 · FY2014 · CA · contact PI
Using Protein Interactome Networks to Understand the Functional Role of Coding DN$411,062
R01 · FY2014 · GM · contact PI
Mechanisms of host-bacterial interactions, ileitis and granuloma formation in Agr$362,004
R01 · FY2014 · DK · contact PI
Whole Genome Sequencing to Discover Familial Myeloma Risk Genes$330,593
R01 · FY2014 · CA · contact PI
DNA Mismatch Repair and associated genes in suppression of GI adenomas and carcin$255,693
R01 · FY2014 · CA · contact PI
Using Protein Interactome Networks to Understand the Functional Role of Coding DN$448,823
R01 · FY2013 · GM · contact PI
Mechanisms of host-bacterial interactions, ileitis and granuloma formation in Agr$342,132
R01 · FY2013 · DK · contact PI
Whole Genome Sequencing to Discover Familial Myeloma Risk Genes$320,150
R01 · FY2013 · CA · contact PI
DNA Mismatch Repair and associated genes in suppression of GI adenomas and carcin$247,785
R01 · FY2013 · CA · contact PI
Whole Genome Sequencing to Discover Familial Myeloma Risk Genes$392,428
R01 · FY2012 · CA · contact PI
Host-bacterial interactions, ileitis and granuloma formation in Agr2-/- mice$388,806
R01 · FY2012 · DK · contact PI
DNA Mismatch Repair and associated genes in suppression of GI adenomas and carcin$263,601
R01 · FY2012 · CA · contact PI
Mechanisms of NOTCH, NUMB and MET signaling in Colon Cancer Initiating Cell Asymm$183,788
R21 · FY2012 · CA · contact PI
DNA Mismatch Repair and associated genes in suppression of GI adenomas and carcin$263,601
R01 · FY2011 · CA · contact PI
Mechanisms of NOTCH, NUMB and MET signaling in Colon Cancer Initiating Cell Asymm$220,545
R21 · FY2011 · CA · contact PI
Mechanisms of Notch Signalling in Colon Cancer Initiating Cells$213,929
R21 · FY2011 · CA · contact PI
In Vitro and In Vivo screening of chemopreventive agents$2,702,092
N01 · FY2010 · CA · contact PI
DNA Mismatch Repair and associated genes in suppression of GI adenomas and carcin$271,753
R01 · FY2010 · CA · contact PI
Mechanisms of Notch Signalling in Colon Cancer Initiating Cells$183,788
R21 · FY2010 · CA · contact PI
UCI 07-70: INHIBITING EGF RECEPTOR SIGNALING IN ABERRANT CRYPT FOCI OF THE COLON$863
M01 · FY2010 · RR · contact PI
PHASE IIA TRIAL TESTING ERLOTINIB AS AN INTERVENTION AGAINST INTRADUCTAL PANCREA$172
M01 · FY2010 · RR · contact PI
In Vitro and In Vivo screening of chemopreventive agents$2,562,872
N01 · FY2009 · CA · contact PI
Mismatch Repair and Associated Genes in Suppression of GI Adenomas and Carcinomas$249,015
R56 · FY2009 · CA · contact PI
DASL-CRC: A Novel Approach to Identify Molecular Markers of Metastatic Recurrence$216,529
R21 · FY2009 · CA · contact PI
PHASE IIA TRIAL TESTING ERLOTINIB AS AN INTERVENTION AGAINST INTRADUCTAL PANCREA$2,264
M01 · FY2009 · RR · contact PI
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$202,241
R01 · FY2008 · CA · contact PI
DASL-CRC: A Novel Approach to Identify Molecular Markers of Metastatic Recurrence$158,998
R21 · FY2008 · CA · contact PI
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$56,610
R01 · FY2008 · CA · contact PI
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$34,900
R01 · FY2008 · CA · contact PI
PHASE IIA TRIAL TESTING ERLOTINIB AS AN INTERVENTION AGAINST INTRADUCTAL PANCREA$1,374
M01 · FY2008 · RR · contact PI
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$237,141
R01 · FY2007 · CA · contact PI
Hypomorphic Mismatch Repair Gene Mutations and Single Molecular MSI Analyses$168,808
R21 · FY2007 · CA · contact PI
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$47,330
R01 · FY2007 · CA · contact PI
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$292,323
R01 · FY2006 · CA · contact PI
Hypomorphic Mismatch Repair Gene Mutations and Single Molecular MSI Analyses$144,875
R21 · FY2006 · CA · contact PI
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$47,980
R01 · FY2006 · CA · contact PI
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$331,890
R01 · FY2005 · CA
Discovery of Novel Genetic Variants Causing Colorectal *$76,250
R03 · FY2005 · CA
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$47,980
R01 · FY2005 · CA
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$28,436
R01 · FY2005 · CA
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$248,734
R01 · FY2004 · CA
Discovery of Novel Genetic Variants Causing Colorectal *$75,834
R03 · FY2004 · CA
Cancer Susceptibility and MSI Analyses of Mlh3 Null Mice$47,980
R01 · FY2004 · CA
Discovery of Novel Genetic Variants Causing Colorectal *$16,477
R03 · FY2004 · CA
MOLECULAR ANALYSES OF MLH3 NULL MICE$148,770
K22 · FY2003 · CA
MOLECULAR ANALYSES OF MLH3 NULL MICE$148,770
K22 · FY2002 · CA
MOLECULAR ANALYSES OF MLH3 NULL MICE$148,770
K22 · FY2001 · CA